使用头孢吡肟/舒巴坦治疗碳青霉烯耐药细菌引起的感染

A. N. Koshmanova, M. Maksimov
{"title":"使用头孢吡肟/舒巴坦治疗碳青霉烯耐药细菌引起的感染","authors":"A. N. Koshmanova, M. Maksimov","doi":"10.33920/med-03-2208-02","DOIUrl":null,"url":null,"abstract":"Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of cefepime/sulbactam in the treatment of infections caused by carbapenem-resistant bacteria\",\"authors\":\"A. N. Koshmanova, M. Maksimov\",\"doi\":\"10.33920/med-03-2208-02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.\",\"PeriodicalId\":406478,\"journal\":{\"name\":\"Glavvrač (Chief Medical Officer)\",\"volume\":\"14 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glavvrač (Chief Medical Officer)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33920/med-03-2208-02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-03-2208-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

头孢吡肟/舒巴坦是一种具有广谱抗菌活性的联合抗生素,包括头孢吡肟(第四代头孢菌素)和舒巴坦(β -内酰胺酶抑制剂),比例为1:1。头孢吡肟/舒巴坦具有杀菌作用:由于阻断转肽酶,导致细胞壁合成紊乱,肽聚糖交联形成紊乱[1]。今天,抗生素耐药性问题正在迅速发展。在世卫组织的清单中,由产esbl的革兰氏阴性菌(对头孢菌素耐药)以及耐碳青霉烯肠杆菌、鲍曼不动杆菌和铜绿假单胞菌引起的感染占据了开发新抗生素的高度优先级别[2]。多重耐药菌引起的感染病程较长,住院时间较长,现代抗菌药物难以治疗,死亡风险增加[3]。在这方面,深入研究单个抗菌药物的作用及其与β-内酰胺酶抑制剂在治疗多重耐药微生物引起的疾病中的作用至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Use of cefepime/sulbactam in the treatment of infections caused by carbapenem-resistant bacteria
Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信